158 related articles for article (PubMed ID: 34687175)
1. Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status.
Iseda N; Itoh S; Yoshizumi T; Tomiyama T; Morinaga A; Yugawa K; Shimokawa M; Shimagaki T; Wang H; Kurihara T; Kitamura Y; Nagao Y; Toshima T; Harada N; Kohashi K; Baba S; Ishigami K; Oda Y; Mori M
Hepatol Commun; 2022 Apr; 6(4):665-678. PubMed ID: 34687175
[TBL] [Abstract][Full Text] [Related]
2. ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma.
Iseda N; Itoh S; Yoshizumi T; Yugawa K; Morinaga A; Tomiyama T; Toshima T; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Apr; 5(4):675-688. PubMed ID: 33860125
[TBL] [Abstract][Full Text] [Related]
3. Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma.
Shimokawa M; Yoshizumi T; Itoh S; Iseda N; Sakata K; Yugawa K; Toshima T; Harada N; Ikegami T; Mori M
Cancer Sci; 2020 Apr; 111(4):1228-1240. PubMed ID: 31968140
[TBL] [Abstract][Full Text] [Related]
4. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
5. NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation.
Ziv E; Zhang Y; Kelly L; Nikolovski I; Boas FE; Erinjeri JP; Cai L; Petre EN; Brody LA; Covey AM; Getrajdman G; Harding JJ; Sofocleous C; Abou-Alfa GK; Solomon SB; Brown KT; Yarmohammadi H
Radiology; 2020 Oct; 297(1):225-234. PubMed ID: 32780006
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
[TBL] [Abstract][Full Text] [Related]
8. IL-1β-Induced Elevation of Solute Carrier Family 7 Member 11 Promotes Hepatocellular Carcinoma Metastasis Through Up-regulating Programmed Death Ligand 1 and Colony-Stimulating Factor 1.
He Q; Liu M; Huang W; Chen X; Zhang B; Zhang T; Wang Y; Liu D; Xie M; Ji X; Sun M; Tian D; Xia L
Hepatology; 2021 Dec; 74(6):3174-3193. PubMed ID: 34288020
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
Koh YW; Lee SJ; Han JH; Haam S; Jung J; Lee HW
Lung Cancer; 2019 Mar; 129():41-47. PubMed ID: 30797490
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma.
Zhang M; Zhang C; Zhang L; Yang Q; Zhou S; Wen Q; Wang J
BMC Cancer; 2015 Jul; 15():531. PubMed ID: 26194347
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of PD-L1 expression combined with hypoxia-associated immunosuppression in hepatocellular carcinoma.
Qian Y; Su H; Ge Y; Lei K; Li Y; Fan H
Biomark Med; 2022 Apr; 16(6):435-448. PubMed ID: 35212229
[No Abstract] [Full Text] [Related]
12. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.
Kasahara N; Kaira K; Bao P; Higuchi T; Arisaka Y; Erkhem-Ochir B; Sunaga N; Ohtaki Y; Yajima T; Kosaka T; Oyama T; Yokobori T; Asao T; Nishiyama M; Tsushima Y; Kuwano H; Shimizu K; Mogi A
Lung Cancer; 2018 May; 119():71-77. PubMed ID: 29656756
[TBL] [Abstract][Full Text] [Related]
13. Impact of albumin-lymphocyte-platelet-C-reactive protein index as a prognostic indicator of hepatocellular carcinoma after resection: Associated with nuclear factor erythroid 2-related factor 2.
Iseda N; Itoh S; Toshida K; Nakayama Y; Ishikawa T; Tsutsui Y; Izumi T; Bekki Y; Yoshiya S; Toshima T; Yoshizumi T
Hepatol Res; 2024 Jan; 54(1):91-102. PubMed ID: 37632704
[TBL] [Abstract][Full Text] [Related]
14. The Expression and Prognostic Value of Cancer Stem Cell Markers, NRF2, and Its Target Genes in TAE/TACE-Treated Hepatocellular Carcinoma.
Tseeleesuren D; Hsiao HH; Kant R; Huang YC; Tu HP; Lai CC; Huang SF; Yen CH
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208536
[No Abstract] [Full Text] [Related]
15. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-
Shrestha R; Bridle KR; Crawford DHG; Jayachandran A
Int J Med Sci; 2021; 18(12):2466-2479. PubMed ID: 34104078
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic effects of nicotinamide in hepatocellular carcinoma through blocking IGF-1 and effecting the balance between Nrf2 and PKB.
Al-Gayyar MMH; Bagalagel A; Noor AO; Almasri DM; Diri R
Biomed Pharmacother; 2019 Apr; 112():108653. PubMed ID: 30784932
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection.
Itoh S; Yugawa K; Shimokawa M; Yoshiya S; Mano Y; Takeishi K; Toshima T; Maehara Y; Mori M; Yoshizumi T
BJS Open; 2019 Aug; 3(4):500-508. PubMed ID: 31388642
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress indicated by elevated expression of Nrf2 and 8-OHdG promotes hepatocellular carcinoma progression.
Ma-On C; Sanpavat A; Whongsiri P; Suwannasin S; Hirankarn N; Tangkijvanich P; Boonla C
Med Oncol; 2017 Apr; 34(4):57. PubMed ID: 28281193
[TBL] [Abstract][Full Text] [Related]
20. Tumor immunity is related to
Imai H; Kaira K; Hashimoto K; Nitanda H; Taguchi R; Yanagihara A; Umesaki T; Yamaguchi O; Mouri A; Kawasaki T; Yasuda M; Kobayashi K; Sakaguchi H; Kuji I; Kagamu H
Cancer Med; 2021 Sep; 10(18):6317-6326. PubMed ID: 34363337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
